Rezolute, Inc. (RZLT)Healthcare | Biotechnology | Redwood City, United States | NasdaqCM
4.74 USD
-0.01
(-0.211%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 4.77 +0.03 (0.633%) ⇧ (July 13, 2026, 6:28 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:34 a.m. EDT
Rezolute presents a classic biotech value trap where a fortress balance sheet masks a deteriorating business trajectory. While the company boasts an impressive current ratio of 15.8x and negligible debt relative to cash, the fundamentals tell a stark story of failure: negative free cash flow, negative operating cash flow, and a trailing EPS of -$0.81. The market has already punished this reality, evidenced by a nearly 88% cumulative decline over the last nine years. Although the latest year saw a rebound (+22.9%), the path to get here was fraught with consecutive declines, and the recent news of a failed Phase 3 trial confirms the lack of a sustainable commercial engine. The high short ratio (7.27) and negative beta suggest the stock is decoupled from broader market moves, likely dragging due to specific sector headwinds. With no dividend to provide income and no proven product pipeline to drive future growth, the 'safe' balance sheet is merely a delay mechanism, not a solution. The options market reflects this uncertainty with heavy speculation on binary outcomes rather than steady appreciation, making this a high-risk environment for capital preservation. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.197464 |
| AutoTheta | 0.224842 |
| AutoETS | 0.225581 |
| AutoARIMA | 0.249974 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 117.44 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.073 |
| Excess Kurtosis | -1.48 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.951 |
| Market Cap | 456,425,600 |
| Forward P/E | -7.57 |
| Beta | 0.55 |
| Website | https://www.rezolutebio.com |
As of July 11, 2026, 3:34 a.m. EDT: Speculators are positioned for continued volatility rather than a clear directional breakout. Call open interest is heavily skewed toward deep out-of-the-money strikes ($10.00) and ATM ($5.00), suggesting bets on a massive rally or binary event. Conversely, put open interest is concentrated at lower strikes ($2.50, $5.00), indicating a floor is expected. The imbalance in volume versus open interest at the $10 strike suggests fresh speculative buying, while the lack of significant ITM call positioning implies skepticism about sustaining a move above current levels without further catalysts.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.107142866 |
| Address1 | 275 Shoreline Drive |
| Address2 | Suite 500 |
| All Time High | 750.0 |
| All Time Low | 0.72 |
| Ask | 5.93 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 2,554,600 |
| Average Daily Volume3 Month | 1,848,921 |
| Average Volume | 1,848,921 |
| Average Volume10Days | 2,554,600 |
| Beta | 0.55 |
| Bid | 3.42 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 1.234 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.74 |
| Current Ratio | 15.842 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.815 |
| Day Low | 4.58 |
| Debt To Equity | 0.951 |
| Display Name | Rezolute |
| Dividend Date | 1,602,547,200 |
| Earnings Timestamp | 1,778,616,000 |
| Earnings Timestamp End | 1,778,616,000 |
| Earnings Timestamp Start | 1,778,616,000 |
| Ebitda | -85,823,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.93 |
| Enterprise Value | 337,268,640 |
| Eps Current Year | -0.695 |
| Eps Forward | -0.62625 |
| Eps Trailing Twelve Months | -0.81 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.0176 |
| Fifty Day Average Change | 0.7223997 |
| Fifty Day Average Change Percent | 0.17980877 |
| Fifty Two Week Change Percent | -10.714287 |
| Fifty Two Week High | 11.457 |
| Fifty Two Week High Change | -6.717 |
| Fifty Two Week High Change Percent | -0.58627915 |
| Fifty Two Week Low | 1.07 |
| Fifty Two Week Low Change | 3.6699996 |
| Fifty Two Week Low Change Percent | 3.429906 |
| Fifty Two Week Range | 1.07 - 11.457 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,358,173,800,000 |
| Float Shares | 66,007,430 |
| Forward Eps | -0.62625 |
| Forward P E | -7.5688615 |
| Free Cashflow | -43,713,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 68 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10152 |
| Held Percent Institutions | 0.90392 |
| Implied Shares Outstanding | 96,292,331 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,602,547,200 |
| Last Split Factor | 1:50 |
| Long Business Summary | Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California. |
| Long Name | Rezolute, Inc. |
| Market | us_market |
| Market Cap | 456,425,600 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_177932577 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -81,485,000 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 457,388,572 |
| Number Of Analyst Opinions | 9 |
| Open | 4.75 |
| Operating Cashflow | -73,484,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 650 206 4507 |
| Post Market Change | 0.03000021 |
| Post Market Change Percent | 0.63291585 |
| Post Market Price | 4.77 |
| Post Market Time | 1,783,981,719 |
| Previous Close | 4.75 |
| Price Eps Current Year | -6.8201437 |
| Price Hint | 4 |
| Price To Book | 3.8411667 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.611 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0100002 |
| Regular Market Change Percent | -0.210531 |
| Regular Market Day High | 4.815 |
| Regular Market Day Low | 4.58 |
| Regular Market Day Range | 4.58 - 4.815 |
| Regular Market Open | 4.75 |
| Regular Market Previous Close | 4.75 |
| Regular Market Price | 4.74 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 2,445,901 |
| Return On Assets | -0.48736998 |
| Return On Equity | -0.81728995 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 96,292,331 |
| Shares Percent Shares Out | 0.17040001 |
| Shares Short | 16,405,419 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 13,716,697 |
| Short Name | Rezolute, Inc. |
| Short Percent Of Float | 0.2565 |
| Short Ratio | 6.05 |
| Source Interval | 15 |
| State | CA |
| Symbol | RZLT |
| Target High Price | 14.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.66667 |
| Target Median Price | 6.0 |
| Total Cash | 120,268,000 |
| Total Cash Per Share | 1.249 |
| Total Debt | 1,111,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.81 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.018925 |
| Two Hundred Day Average Change | -0.27892542 |
| Two Hundred Day Average Change Percent | -0.05557473 |
| Type Disp | Equity |
| Volume | 2,445,901 |
| Website | https://www.rezolutebio.com |
| Zip | 94,065 |